Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Discovery of target genes and pathways of blood trait loci using pooled CRISPR screens and single cell RNA sequencing

ABSTRACT: Discovery of target genes and pathways of blood trait loci using pooled CRISPR screens and single cell RNA sequencing

PROVIDER: PRJNA719672 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14141135_1.fastq.gz	Fastqsanger.gz
	SRR14141135_2.fastq.gz	Fastqsanger.gz
	SRR14141136_1.fastq.gz	Fastqsanger.gz
	SRR14141136_2.fastq.gz	Fastqsanger.gz
	SRR14141137_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 284

Similar Datasets

Discovery of target genes and pathways of blood trait loci using pooled CRISPR screens and single cell RNA sequencing

Project description:The majority of variants associated with complex traits and common diseases identified by genome-wide association studies (GWAS) map to noncoding regions of the genome with unknown regulatory effects. By leveraging ancestrally diverse biobank-scale GWAS data, massively parallel CRISPR screens and single cell transcriptomic and proteomic sequencing, we discovered target genes of noncoding variants for blood trait loci. For 91 GWAS loci, we identified 124 target genes in cis, which were often — but not always — the closest genes to the fine-mapped variant. Using precise variant insertion via base editing, we connect specific variants with gene expression changes. We also identified trans-effect networks of noncoding loci when cis target genes encoded transcription factors or microRNAs, such as GFI1B and miR-142. Trans-regulatory networks were themselves enriched for fine-mapped GWAS variants, demonstrating polygenic contributions to complex traits. Co-expression clustering of GFI1B trans-target genes identifies gene networks specific to different blood cell fates and differentiation stages. This platform will enable massively parallel assays to characterize the target genes and mechanisms of human noncoding variants in both cis and trans.

2021-04-08 | GSE171452 | GEO

Pooled CRISPR screens in human intestinal organoids [CRISPR screens]

Project description:Pooled CRISPR screens in human intestinal organoids [CRISPR screens]

| PRJNA608420 | ENA

Multiplexed Perturbation Enables Scalable Pooled Screens

Project description:Multiplexed Perturbation Enables Scalable Pooled Screens

| PRJNA1290110 | ENA

Pooled CRISPR screens in human macrophages

Project description:Pooled CRISPR screens in human macrophages

| PRJNA893203 | ENA

Discovery of target genes and pathways at GWAS loci by pooled single-cell CRISPR screens.

Project description:Most variants associated with complex traits and diseases identified by genome-wide association studies (GWAS) map to noncoding regions of the genome with unknown effects. Using ancestrally diverse, biobank-scale GWAS data, massively parallel CRISPR screens, and single-cell transcriptomic and proteomic sequencing, we discovered 124 cis-target genes of 91 noncoding blood trait GWAS loci. Using precise variant insertion through base editing, we connected specific variants with gene expression changes. We also identified trans-effect networks of noncoding loci when cis target genes encoded transcription factors or microRNAs. Networks were themselves enriched for GWAS variants and demonstrated polygenic contributions to complex traits. This platform enables massively parallel characterization of the target genes and mechanisms of human noncoding variants in both cis and trans.

| S-EPMC10518238 | biostudies-literature

Pooled CRISPR screens in human intestinal organoids

Project description:Pooled CRISPR screens in human intestinal organoids

| PRJNA608374 | ENA

Multiplexed Perturbation Enables Scalable Pooled Screens

Project description:CRISPR-based genetic perturbation screens have revolutionized the ability to link genes to cellular phenotypes with unprecedented precision and scale. However, conventional pooled CRISPR screens require large cell numbers to achieve adequate sgRNA representation, posing technical and financial challenges. Here, we investigate the impact of multiplexed sgRNA delivery via high multiplicity of infection (MOI) in pooled CRISPR interference (CRISPRi) screens as a strategy to enhance screening efficiency while reducing cell numbers. We systematically evaluate screen performance across varying MOIs, assessing the effects of multiplexing on knockdown efficiency, sgRNA representation, and collision rates. Our data demonstrate that sgRNA multiplexing (MOI 2.5-10) can maintain screen performance while enabling significant reductions in cell requirements. We further apply these optimized conditions to conduct a genome-wide CRISPR screen for regulators of intracellular adhesion molecule ICAM-1, successfully identifying novel candidates using as few as half a million cells. This study provides a framework for adopting multiplexed sgRNA strategies to streamline CRISPR screening applications in resource-limited settings.

2026-01-16 | GSE302335 | GEO

In Vivo pooled CRISPRko screens in PDA Cell Lines

Project description:In Vivo pooled CRISPRko screens in PDA Cell Lines

| PRJNA1128635 | ENA

Pooled CRISPR screens in human intestinal organoids [RNA-seq]

Project description:Pooled CRISPR screens in human intestinal organoids [RNA-seq]

| PRJNA608809 | ENA

Pooled CRISPR screens in human intestinal organoids [CUT&RUN]

Project description:Pooled CRISPR screens in human intestinal organoids [CUT&RUN]

| PRJNA608810 | ENA